Emergent Biosolutions Inc Stock Price, News & Analysis

Emergent BioSolutions (NYSE:EBS) announced the publication of a review article in Expert Review of Anti-infective Therapy evaluating brincidofovir as a potential treatment for mpox. The article examines brincidofovir's in vitro and in vivo data, human case studies, and its current evaluation in the Democratic Republic of Congo.

The publication comes amid ongoing global mpox outbreaks, with the WHO declaring a Public Health Emergency of International Concern (PHEIC) on August 14, 2024. Brincidofovir is being evaluated in the MpOx Study in Africa (MOSA), a double-blind, placebo-controlled clinical trial that began in January 2025, conducted in partnership with PANTHER and funded by Horizon Europe and Africa CDC.

Emergent BioSolutions (NYSE:EBS) has scheduled its second quarter 2025 financial results conference call for August 6, 2025, at 5:00 PM ET. The company will provide access to the call through multiple channels, including a live webcast available on their Investors webpage.

Telephone participants must pre-register through a provided link to receive dial-in information and unique access credentials. A replay of the conference call will be made available on the company's Investors page after the event.

Emergent BioSolutions (NYSE:EBS) has secured a significant $51.9 million contract modification from the Administration for Strategic Preparedness and Response (ASPR) for its CNJ-016® (VIGIV) treatment. The contract is part of the U.S. government's smallpox preparedness strategy, extending an existing 10-year agreement for additional doses of VIGIV, which treats complications from smallpox vaccination.

The announcement follows Emergent's recent BAT® (Botulism Antitoxin Heptavalent) contract amendment with ASPR. VIGIV is a 5% Liquid Immune Globulin treatment indicated for various vaccinia vaccination complications, including eczema vaccinatum and progressive vaccinia, though not for postvaccinial encephalitis.

Emergent BioSolutions (NYSE:EBS) has expanded its NARCANDirect® online distribution network to include KLOXXADO® (naloxone HCl) Nasal Spray 8 mg, complementing its existing NARCAN® 4 mg nasal spray offering. The expansion, effective July 1, 2025, follows Emergent's acquisition of KLOXXADO's exclusive commercial rights in the U.S. and Canada in January 2025.

The platform serves qualified direct purchasers including emergency services, law enforcement, schools, and community-based programs. The company is also introducing Convenience Kits featuring CPR masks and nitrile gloves. This expansion comes as CDC data shows a 27% decrease in drug overdose deaths in 2024, though recent data indicates a slight uptick of 1,400 deaths between January 2024 and January 2025.

Emergent BioSolutions (NYSE: EBS) has secured a $62.4 million contract modification from the Administration for Strategic Preparedness and Response (ASPR) for their BAT® (Botulism Antitoxin Heptavalent) product. This modification extends their existing 10-year contract with ASPR for supplying BAT®, a treatment for symptomatic botulism exposure to neurotoxin serotypes A through G in both adults and children. The contract reinforces the U.S. government's commitment to maintaining critical medical countermeasures in its biodefense stockpile. Emergent BioSolutions will leverage its North American supply chain to deliver this life-saving solution, contributing to public health protection and global emergency preparedness.

Emergent BioSolutions (NYSE: EBS) announced its upcoming addition to the Russell 3000® Index, effective after market close on June 27, 2025. This inclusion comes as part of the annual reconstitution of Russell U.S. stock indexes, which captures the 4,000 largest U.S. stocks based on market capitalization. CEO Joe Papa highlighted this as a significant milestone in Emergent's transformation, indicating positive momentum and positioning for disciplined growth. Membership in the Russell 3000® automatically includes the company in either the Russell 1000® or Russell 2000® Index. The Russell indexes are significant benchmarks for investment strategies, with approximately $10.5 trillion in assets benchmarked against them as of December 2023.

Emergent BioSolutions (NYSE: EBS) is collaborating with Victoria's Voice Foundation for National Naloxone Awareness Day on June 6, launching the 'Shine. Wear. Share. Care' campaign to combat opioid overdoses. The campaign includes educational resources and NARCAN® Nasal Spray distribution. CDC data shows a significant 27% decrease in drug overdose deaths in 2024, with opioid-related deaths dropping 34% from 2023. Emergent distributes both OTC NARCAN® Nasal Spray and prescription KLOXXADO® Nasal Spray to expand access to life-saving naloxone. Through their Ready to Rescue initiative, Emergent works to reduce stigma and increase opioid emergency preparedness education. The company is partnering with various organizations to make NARCAN® more accessible across different industries.

Emergent BioSolutions (NYSE: EBS) has announced its participation in multiple upcoming investor conferences in May and June 2025. The company's executive management team will attend:

- RBC Global Healthcare Conference in New York (May 20) featuring a fireside chat at 3:35 pm ET
- Goldman Sachs Leveraged Finance Conference in Dana Point, California (May 29)
- Benchmark's 5th Annual Healthcare House Call Virtual Investor Conference (May 29)
- Jefferies Global Healthcare Conference in New York (June 5) with a presentation at 1:25 pm ET

Virtual attendance options are available for select events, and presentation replays will be accessible through Emergent's website investor page.

Emergent BioSolutions (NYSE: EBS) reported Q1 2025 financial results with total revenues of $222.2M, down 26% year-over-year. Despite lower revenues, the company showed significant profitability improvements with net income of $68M, up 656% from Q1 2024. Key metrics include gross margin of 50% and adjusted EBITDA of $77.6M, up 16%. Notable business updates include securing contracts worth $20M for BioThrax supply to U.S. DoD, $16.7M for Ebanga development, and a $65M agreement with Ontario for NARCAN supply. The company completed the sale of its Baltimore-Bayview facility for $36.5M and announced a $50M stock buyback program. Product sales showed mixed performance: NARCAN sales declined 62% to $45.3M, Anthrax MCM decreased 14% to $47.9M, while Smallpox MCM increased 112% to $106.4M. The company reaffirmed its FY 2025 guidance with expected revenues of $750M-$850M and adjusted EBITDA of $150M-$200M.